explore -WSS

explore

author：leisure time 2025-10-01 14:38:00 - browse：4831

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： New requirements coming in 2024 for Americans traveling to Europe

leisure time

WSS

Statins reduce cardiovascular risk in people living with HIV

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

My chronic pain journey would have been easier knowing 5 things % STAT

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Readers respond to H5N1 and livestock movements, and more

Data integrity in scientific journals requires "effort" by publishers, institutions

entertainment

explore

hotspot

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Cancer drug shortages should be causing more outrage

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Jerome Adams on the need for new antivirals for Covid

Burning questions about Delta and the next phase of the Covid pandemic

Dobbs anniversary: the lost opportunity of abortion as health care

Readout LOUD podcast: Live from STAT Breakthrough Summit West

How to save PrEP access — and even expand it

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

hotspot

Cytokinetics CEO stresses company can launch heart drug on its own

Second House panel advances two

Solving academic medical centers' existential crisis

What Henrietta Lacks's story taught me about my role as a doctor

PrEP can help anyone prevent HIV. Why do so few people take it?

Novartis develops a rapidly manufactured CAR

entertainment

leisure time

hotspot

leisure time